Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.84
(
-0.57%
)
Bitcoin
70,864.27
(
1.38%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 205822

Monday, 11/07/2016 7:54:59 PM

Monday, November 07, 2016 7:54:59 PM

Post# of 257262
ABBV/AMGN/CHRS/MNTA—In general, I don't expect formulation patents on Humira such as the one in the USPTO ruling today to be a significant impediment to commercialization of Humira FoBs. They ought to be pretty easy to work around, IMO. (See #msg-118781959 for related discussion.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now